|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Michigan Oncology Journal Spring 98
James Ferrara, M.D.
Professor of Medicine and Pediatrics
Director, Adult and Pediatric Blood and Marrow Transplant Program
Area of expertise:
bone marrow transplantation
Research interests: mechanisms of graft-versus-host disease and graft- versus-tumor effects in leukemia patients
Diane Simeone, M.D.
Assistant Professor of Surgery
Area of expertise:
the role of tumor suppressor genes in pancreatic carcinogenesis and the potential role of gene therapy for the treatment of pancreatic cancer
The U-M Cranial Base Program is one of the largest programs in the United States addressing neoplasms, as well as acquired and congenital abnormalities at both the anterior and lateral skull base. For more specific information about faculty and staff, conditions treated, outcomes, and medical technology used, visit our web site at: www.med.umich.edu/oto/cranial-base-program.
Phase II biomarker chemoprevention trial for women with biopsy proven CIN II or CIN III. This study will determine whether HPV copy number and E6/E7 expression are predictors of response to all-trans Retinoic Acid (atRA). Participants receive treatment with (atRA) or placebo applied to the cervix with a cervical cap daily for four days, HPV testing and cervicography included. A 12-week follow up colposcopy with biopsy is reimbursed.
The University of Michigan Comprehensive Cancer Center is participating in the second breast cancer prevention trial sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP). This study, known as STAR (Study of Tamoxifen And Raloxifene), is being conducted throughout the United States and Canada. Participants will be randomized to receive either tamoxifen (Nolvadex) or raloxifene (Evista). Eligible patients include post-menopausal women with LCIS, atypical hyperplasia, a family history or other significant risk factors. Patients are ineligible if they have a history of previous intraductal or invasive carcinoma of the breast, DVT, PE, CVA or TIA. Current coumadin, cholestyramine, estrogen or progesterone use is prohibited.
A National Cancer Institute-sponsored Phase I trial for patients with recurrent epithelial ovarian cancer who have failed chemotherapy has been activated. Patients receive a vaccine made from dendritic cells pulsed with autologous ovarian cancer tumor cell lysate. Eligibility criteria include a source of tumor cells (effusion or solid tumor), measurable disease and a life expectancy of at least three months.
A Phase II trial of tandem high-dose chemo-therapy with stem cell support in patients with metastatic, locally recurrent breast cancer or newly diagnosed disease with at least partial response to first-line chemotherapy. Induction chemotherapy (for those previously untreated) consists of doxorubicin and taxotere with mobilization of peripheral blood progenitor cells (PBPC). The first high-dose consolidation includes cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2, and carboplatin 800 mg/m2 with PBPC and is administered as an in-patient. After complete recovery from the first high-dose treatment, a second high-dose consolidation of melphalan 180 mg/m2 and taxol mg/m2 is given with PBPC and is administered as an out-patient. Post-transplant radiotherapy or surgery to sites of bulk disease, and/or anti-hormonal therapy may be needed. Studies of immune reconstitution for one-year post-transplant are performed, in preparation for future trials of immunotherapy (including tumor vaccines).